S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
WSC Sports Was Built on a Love for Sports. It Changed The Entire Game.
Is This The End of Capitalism? (Ad)
Why Lucid Spiked Nearly 100% In One Day
Ride These Railroad Stocks for Growth and Income
The Next Big Crisis Is Here (Ad)
EVs, Robotics Among Growth Drivers As Chipmaker STMicro Gaps Up
ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
Is This The End of Capitalism? (Ad)
Microsoft’s Comeback Is Now Underway
Asian shares edge higher, tracking Wall Street rally
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
WSC Sports Was Built on a Love for Sports. It Changed The Entire Game.
Is This The End of Capitalism? (Ad)
Why Lucid Spiked Nearly 100% In One Day
Ride These Railroad Stocks for Growth and Income
The Next Big Crisis Is Here (Ad)
EVs, Robotics Among Growth Drivers As Chipmaker STMicro Gaps Up
ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
Is This The End of Capitalism? (Ad)
Microsoft’s Comeback Is Now Underway
Asian shares edge higher, tracking Wall Street rally
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
WSC Sports Was Built on a Love for Sports. It Changed The Entire Game.
Is This The End of Capitalism? (Ad)
Why Lucid Spiked Nearly 100% In One Day
Ride These Railroad Stocks for Growth and Income
The Next Big Crisis Is Here (Ad)
EVs, Robotics Among Growth Drivers As Chipmaker STMicro Gaps Up
ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
Is This The End of Capitalism? (Ad)
Microsoft’s Comeback Is Now Underway
Asian shares edge higher, tracking Wall Street rally
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
WSC Sports Was Built on a Love for Sports. It Changed The Entire Game.
Is This The End of Capitalism? (Ad)
Why Lucid Spiked Nearly 100% In One Day
Ride These Railroad Stocks for Growth and Income
The Next Big Crisis Is Here (Ad)
EVs, Robotics Among Growth Drivers As Chipmaker STMicro Gaps Up
ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
Is This The End of Capitalism? (Ad)
Microsoft’s Comeback Is Now Underway
Asian shares edge higher, tracking Wall Street rally
NASDAQ:NUVA

NuVasive - NUVA Stock Forecast, Price & News

$45.91
+0.96 (+2.14%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$44.90
$45.98
50-Day Range
$36.24
$46.11
52-Week Range
$35.17
$60.47
Volume
272,340 shs
Average Volume
509,458 shs
Market Capitalization
$2.39 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.62

NuVasive MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
12.4% Upside
$51.62 Price Target
Short Interest
Bearish
7.10% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.56mentions of NuVasive in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
5.88%
From $2.04 to $2.16 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.62 out of 5 stars

Medical Sector

934th out of 1,055 stocks

Surgical & Medical Instruments Industry

98th out of 105 stocks


NUVA stock logo

About NuVasive (NASDAQ:NUVA) Stock

NuVasive, Inc. engages in the development, manufacture, sale, and provision of procedural solutions for spine surgery. It offers a comprehensive portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. The company was founded by Alexis V. Lukianov on July 21, 1997 and is headquartered in San Diego, CA.

Receive NUVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NuVasive and its competitors with MarketBeat's FREE daily newsletter.

NUVA Stock News Headlines

Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
NuVasive (NUVA) Suffers From Macro Headwinds, Price Issue
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
NuVasive: An Excellent Growth Story In Spine Surgery
NuVasive (NUVA) Q3 Earnings Beat Estimates, Guidance Cut
NuVasive Third Quarter 2022 Earnings: Misses Expectations
NuVasive Announces Third Quarter 2022 Financial Results
NuVasive (NUVA) Surpasses Q3 Earnings Estimates
See More Headlines
Receive NUVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NuVasive and its competitors with MarketBeat's FREE daily newsletter.

NUVA Company Calendar

Last Earnings
11/09/2022
Today
1/27/2023
Next Earnings (Estimated)
2/22/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:NUVA
CUSIP
67070410
Employees
2,900
Year Founded
1997

Price Target and Rating

Average Stock Price Forecast
$51.62
High Stock Price Forecast
$63.00
Low Stock Price Forecast
$44.00
Forecasted Upside/Downside
+12.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
$-64,090,000.00
Pretax Margin
-1.13%

Debt

Sales & Book Value

Annual Sales
$1.14 billion
Cash Flow
$4.81 per share
Book Value
$15.37 per share

Miscellaneous

Free Float
51,889,000
Market Cap
$2.39 billion
Optionable
Optionable
Beta
0.96

Social Links


Key Executives

  • J. Christopher BarryJ. Christopher Barry
    Chief Executive Officer & Director
  • Dale Wolf
    Senior Vice President-Global Operations
  • Matthew K. Harbaugh
    Chief Financial Officer & Executive Vice President
  • Kyle Malone
    Vice President-Scientific Affairs
  • Ryan Donahoe
    Chief Technology Officer & Senior Vice President













NUVA Stock - Frequently Asked Questions

Should I buy or sell NuVasive stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NUVA shares.
View NUVA analyst ratings
or view top-rated stocks.

What is NuVasive's stock price forecast for 2023?

9 brokers have issued 12 month price objectives for NuVasive's stock. Their NUVA share price forecasts range from $44.00 to $63.00. On average, they anticipate the company's share price to reach $51.62 in the next twelve months. This suggests a possible upside of 12.4% from the stock's current price.
View analysts price targets for NUVA
or view top-rated stocks among Wall Street analysts.

How have NUVA shares performed in 2023?

NuVasive's stock was trading at $41.24 at the beginning of the year. Since then, NUVA stock has increased by 11.3% and is now trading at $45.91.
View the best growth stocks for 2023 here
.

When is NuVasive's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our NUVA earnings forecast
.

How were NuVasive's earnings last quarter?

NuVasive, Inc. (NASDAQ:NUVA) announced its quarterly earnings data on Wednesday, November, 9th. The medical device company reported $0.54 EPS for the quarter, topping analysts' consensus estimates of $0.53 by $0.01. The medical device company earned $295.30 million during the quarter, compared to the consensus estimate of $298.76 million. NuVasive had a negative net margin of 1.70% and a positive trailing twelve-month return on equity of 12.49%. The firm's quarterly revenue was up 9.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.32 earnings per share.

How will NuVasive's stock buyback program work?

NuVasive declared that its board has approved a stock buyback plan on Tuesday, November 9th 2021, which authorizes the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 3.5% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's leadership believes its stock is undervalued.

What guidance has NuVasive issued on next quarter's earnings?

NuVasive issued an update on its FY 2022 earnings guidance on Friday, December, 9th. The company provided earnings per share (EPS) guidance of $2.00-$2.10 for the period, compared to the consensus estimate of $2.24. The company issued revenue guidance of $1.20 billion-$1.21 billion, compared to the consensus revenue estimate of $1.22 billion.

What is Chris Barry's approval rating as NuVasive's CEO?

59 employees have rated NuVasive Chief Executive Officer Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among the company's employees.

What other stocks do shareholders of NuVasive own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT).

What is NuVasive's stock symbol?

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

Who are NuVasive's major shareholders?

NuVasive's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Stephens Investment Management Group LLC (1.54%), Scout Investments Inc. (0.60%), Ziegler Capital Management LLC (0.27%), Assenagon Asset Management S.A. (0.17%), Profit Investment Management LLC (0.14%) and New York State Teachers Retirement System (0.10%). Insiders that own company stock include James Christopher Barry, Lucas Vitale, Massimo Calafiore and Matthew Link.
View institutional ownership trends
.

How do I buy shares of NuVasive?

Shares of NUVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NuVasive's stock price today?

One share of NUVA stock can currently be purchased for approximately $45.91.

How much money does NuVasive make?

NuVasive (NASDAQ:NUVA) has a market capitalization of $2.39 billion and generates $1.14 billion in revenue each year. The medical device company earns $-64,090,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis.

How many employees does NuVasive have?

The company employs 2,900 workers across the globe.

Does NuVasive have any subsidiaries?
The following companies are subsidiares of NuVasive: Biotronic NeuroNetwork, Ellipse Technologies, NuVasive Clinical Services Monitoring Inc., NuVasive Japan KK, NuVasive Specialized Orthopedics Inc., NuVasive Technology International Limited, SafePassage, Simplify Medical, and Vertera Spine.
Read More
How can I contact NuVasive?

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The official website for the company is www.nuvasive.com. The medical device company can be reached via phone at (858) 909-1800, via email at investorrelations@nuvasive.com, or via fax at 800-475-9134.

This page (NASDAQ:NUVA) was last updated on 1/28/2023 by MarketBeat.com Staff